Home » Watson R&D Spending Rises for Generic Pharmaceuticals
Watson R&D Spending Rises for Generic Pharmaceuticals
Watson Pharmaceuticals has increased its generic
R&D spending by 17 percent to $37 million during the third quarter as it awaits FDA action on about
60 ANDAs under review. Overall R&D spending grew 15 percent to $52 million, CEO Paul Bisaro said on the drugmaker’s third-quarter earnings call.
Generic Line
Generic Line
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May